Entity Details

Primary name CFAB_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP00751
EntryNameCFAB_HUMAN
FullNameComplement factor B
TaxID9606
Evidenceevidence at protein level
Length764
SequenceStatuscomplete
DateCreated1986-07-21
DateModified2021-06-02

Ontological Relatives

GenesCFB

GO terms

Show/Hide Table
GOName
GO:0001848 complement binding
GO:0004252 serine-type endopeptidase activity
GO:0005576 extracellular region
GO:0005615 extracellular space
GO:0005886 plasma membrane
GO:0006956 complement activation
GO:0006957 complement activation, alternative pathway
GO:0030449 regulation of complement activation
GO:0070062 extracellular exosome
GO:0072562 blood microparticle

Subcellular Location

Show/Hide Table
Subcellular Location
Secreted

Domains

Show/Hide Table
DomainNameCategoryType
IPR000436 Sushi/SCR/CCP domainDomainDomain
IPR001254 Serine proteases, trypsin domainDomainDomain
IPR001314 Peptidase S1A, chymotrypsin familyFamilyFamily
IPR002035 von Willebrand factor, type ADomainDomain
IPR009003 Peptidase S1, PA clanFamilyHomologous superfamily
IPR011360 Complement B/C2FamilyFamily
IPR018114 Serine proteases, trypsin family, histidine active siteSiteActive site
IPR028341 Complement factor BFamilyFamily
IPR033116 Serine proteases, trypsin family, serine active siteSiteActive site
IPR035976 Sushi/SCR/CCP superfamilyFamilyHomologous superfamily
IPR036465 von Willebrand factor A-like domain superfamilyFamilyHomologous superfamily
IPR043504 Peptidase S1, PA clan, chymotrypsin-like foldFamilyHomologous superfamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
615561 OMIMComplement factor B deficiency (CFBD)An immunologic disorder characterized by increased susceptibility to bacterial infections, particularly Neisseria infections, due to a defect in the alternative complement pathway. The disease is caused by variants affecting the gene represented in this entry.
615489 OMIMMacular degeneration, age-related, 14 (ARMD14)A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Disease susceptibility may be associated with variants affecting the gene represented in this entry. Haplotype analyses have identified a statistically significant common risk haplotype and two protective haplotypes. CFB variant His-9 and C2 variant Asp-318, as well as CFB variant Gln-32 and a variant in intron 10 of C2, confer a significantly reduced risk of AMD.
612924 OMIMHemolytic uremic syndrome atypical 4 (AHUS4)An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Disease susceptibility is associated with variants affecting the gene represented in this entry. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.

Drugs

Show/Hide Table
DrugNameSourceType
DB01593 ZincDrugbanksmall molecule
DB02459 4-guanidinobenzoic acidDrugbanksmall molecule
DB04491 Diisopropylphosphono GroupDrugbanksmall molecule
DB06503 MLN2222Drugbankbiotech
DB14487 Zinc acetateDrugbanksmall molecule